~~<i id='B87183AED3'><strike id='B87183AED3'><tt id='B87183AED3'><pre id='B87183AED3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：hotspot 2025-09-29 23:28:12 - browse：2679

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Generate Biomedicines machine learning biotech raises $273M

focus

knowledge

leisure time

entertainment

focus

entertainment

FILE-PrinceHarryleavestheHighCourtaftergivingevidenceinLondon,Wednesday,June7,2023.PrinceHarryisseek

WSS

The simple reason for the increase in autism diagnosis

How medical schools plan to diversify without affirmative action

Ukrainian soldiers say they owe lives to US

The strange history of BMI, the body mass index

New weight loss drugs vying to be the next Wegovy or Mounjaro

Brazil's Jair Bolsonaro is barred from running for office until 2030

focus

explore

focus

How one medical school became remarkably diverse

Illumina to lay off 10% of research and development team

Trump demands the U.S. pay no more for drugs than other countries … again

A common UTI test for kids haunts adults as a traumatic 'nightmare'

The cancer drug shortage isn’t new — and neither are the solutions

Medical experts exlpore how to eliminate bias in clinical algorithms

Malaria cases in Florida and Texas: Here’s what you need to know

Diverse clinical trials: Why aren’t we there yet?

Peter Hotez and the public health issue of online harassment

Supreme Court rules employers must be more accommodating of religious observance

knowledge

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

WATCH: Why do bright lights make us see spots?

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

UnitedHealth wins $3.3 billion takeover of Amedisys

UnitedHealth wins $3.3 billion takeover of Amedisys

FDA panel endorses Alnylam’s heart drug — after picking it apart

leisure time

entertainment

focus

entertainment